BT-7480 is under clinical development by Bicycle Therapeutics and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase II drugs for Esophageal Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BT-7480’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BT-7480 overview
BT-7480 is under development for the treatment of advanced solid tumors including urothelial (transitional cell) carcinoma, anal cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, ovarian cancer, breast cancer, gastric cancer, cervical cancer and esophageal carcinoma. The drug candidate is developed based on bicyclic peptides (Bicycles) technology composed of bicyclic peptides. It is T-cell modulators acts by targeting CD137 and nectin-4. It is administered through intravenous route.
Bicycle Therapeutics overview
Bicycle Therapeutics is a biotechnology company. It develops bicyclic peptides and Medicines for the treatment of cancers and other debilitating diseases. The company’s Bicycle conjugates include BT1718, BT5528, and BT8009; and Immuno-Oncology offers BT7480, BT7401, and BT7455. Bicycle Therapeutics proprietary bicyclic peptide technology enables the systematic cyclisation of peptides and helps to identify bicycles that provide antibody-like affinity and selectivity in a much smaller chemically synthesized molecule. The company operates with other biotechnology companies for the development of bicyclic peptide inhibitors for the treatment of ophthalmic diseases such as diabetic macular edema, renal elimination, versatility for multimerization and conjugation. It works in collaboration with Cancer Research UK(CRUK), and AstraZeneca Plc in the areas of oncology, respiratory, cardiovascular, and metabolic diseases, among others. Bicycle Therapeutics is headquartered in Cambridge, Cambridgeshire, the UK.
For a complete picture of BT-7480’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
